Left Ventricular Assist Devices: The What and the Who Lance E. Sullenberger MD FACC FACP Capital Cardiology Associates.

Slides:



Advertisements
Similar presentations
Advance Heart Failure Therapy
Advertisements

 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
Congestive heart failure
Can Comparative Effectiveness Study Tell Us What Is The Best Therapy For Class IV Heart Failure? Beta blockers or LVADs?
Innovative Minimally Invasive Circulatory Assist Device.
Topics Zoll LifeVest  What it is  Who it treats  How does EMS handle these patients?
1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –
Prepared by : Nehad J. Ahmed.  Heart failure, also known as congestive heart failure (CHF), means your heart can't pump enough blood to meet your body's.
The Heart and Heart Failure in the Year 2013 Jonathan D. Rich, MD Associate Director, Mechanical Circulatory Support Program Bluhm Cardiovascular Institute.
Case Studies Advanced Heart Failure and the Role of Mechanical Circulatory Support Megan Shifrin, RN, MSN, ACNP-BC Vanderbilt University.
Dean Handimulya UIEU 2005 Congestive Heart Failure Dean Handimulya, M.D.
Heart Transplantation for Patients with a Fontan Procedure
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
Rejection Normal response Inflammation 25% of pt. will have acute rejection during the first year post transplant Causes: Previous Rejection Noncompliance.
Introduction to Ventricular Assist Device (VAD)
Lifestyles, Fitness and Rehabilitation Heart Failure.
HEART FAILURE Prevalence increasing in our ageing population Incidence doubles with each decade between 40 and 80 At any age more common in men than women.
Biventricular Failure – Total Artificial Heart Francisco A. Arabía, MD Director, CHSI Center for Surgical Device Management Cedars-Sinai Heart Institute.
Treatment of Heart Failure: Beyond Medical Therapy
Ventricular Assist Device: An Advanced Surgical Intervention for the Treatment of End Stage Heart Failure Laura Coyle, MSN, ACNP-BC VAD Coordinator Advocate.
The failing heart; Update in surgical treatment Gunnar Myrdal MD. PhD, Reykjavik University Hospital. ICELAND.
An interesting case… Karen Neoh.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Do Medical Research And New Technology Actually Make Our Lives Better? Darrell G. Kirch, M.D. March 31, 2004.
Stress Cardiomyopathy Presented by Brittney Howard, PA-S Advised by Bill Grimes, Dmin, PA-C Presented by Brittney Howard, PA-S Advised by Bill Grimes,
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
Next Generation Cardiac Assist Devices Society for Medical Innovation and Technology May 2006 Pebble Beach, Monterey, CA, USA presented to Jeffrey.
Frank-Starling Mechanism
Nursing and heart failure
Surgical outcome of native valve infective endocarditis in srinagarind hospital
Professor Davor Miličić, MD, PhD, FESC MECHANICAL SUPPORT TO THE FAILING HEART Department of Cardiovascular Medicine, Zagreb University School of Medicine,
Linda S. Williams / Paula D. Hopper Copyright © F.A. Davis Company Understanding Medical Surgical Nursing, 4th Edition Chapter 26 Nursing Care of.
TREATMENT OF HEART FAILURE From Oral Medications to Intravenous Drips Mark Puhlman MSN ANP.
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
 39 year old Male  Single, no children  Lives in a 2 story home alone?  Lives in a 1 story home with brother?  Lives in a 3 story home with sister?
Heart Failure Clinic Facility: James A Haley VAMC, Tampa FL Contact Person: Jeannette McCain, MA, ARNP-C
Coronary Heart Disease. Coronary Heart Muscle  Coronary arteries and veins are found within heart muscle  Blood Clots  Coronary thrombosis  Coronary.
Advanced Therapies Lee R. Goldberg, MD, MPH Medical Director, Heart Failure and Cardiac Transplant Program University of Pennsylvania.
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
– Dr. J. Satish Kumar, MD, Department of Basic & Medical Sciences, AUST General Medicine CVS Name:________________________________________ Congestive Heart.
Internal Medicine Workshop Series Laos September /October 2009
Heart Failure Cardiac Insufficiency. What is Heart Failure? Heart failure is a progressive disorder in which damage to the heart causes weakening of the.
Heart Failure What is Heart Failure? The heart is not pumping properly.  Usually, the heart has been weakened by an underlying condition  Blocked arteries.
Ihab Alomari, MD, FACC Assistant professor – Interventional Cardiology University of California, Irvine Division of Cardiology Cath Lab Essentials : LV.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
CONGESTIVE HEART FAILURE Definition: Heart failure occurs when the output from the heart is no longer able to meet the body's metabolic demands for oxygen.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of the Destination Therapy Post-Food and.
Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:
Total Artificial Heart (TAH): Survival Outcomes, Risk Factors,
University of Chicago Medicine
Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,
Ventricular Assist Device
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
Congestive heart failure
Medical-Surgical Nursing: Concepts & Practice
The Use of Impella for CGS Patients Does It Save Lives?
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) – Long Term Outcomes.
Diseases of the heart muscle
Mechanical Circulatory Support Devices HOSEIN PASANDI.
Durable Mechanical Circulatory Support in Advanced Heart Failure
Nursing Care of Patients with Heart Failure
Figure 1 Ventricular end-diastolic pressure–volume relationship curves
Left Ventricular Assist Device Destination Therapy Versus Extended Criteria Cardiac Transplant  Mani A. Daneshmand, MD, Keshava Rajagopal, MD, PhD, Brian.
Dr Satti Abdelrahim Satti Pediatric Consultant
Next Generation Cardiac Assist Devices
Jerry D. Estep et al. JCHF 2013;1:
Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011  William L.
Khalid AlHabib Professor of Cardiac Sciences Cardiology Consultant
Presentation transcript:

Left Ventricular Assist Devices: The What and the Who Lance E. Sullenberger MD FACC FACP Capital Cardiology Associates

US Heart Transplants StableBut Heart Failure Increasing…

Left Ventricular Assist Device Pulsatile Flow Not a true artificial heart. Assists the left ventricle in passing oxygenated blood through the body. Initially was a pulsatile device (similar to native heart…)

Left Ventricular Assist Device Continuous (Axial) Flow

Pulsatile Flow is Out Axial Flow is In

The Down Side Infection Bleeding Thrombosis Embolism Battery issues Hemolysis

Who Gets an LVAD? Bridge to Recovery Bridge to Transplant Destination Therapy

Bridge to Recovery Acute Myocarditis Acute Myocardial Infarction Peripartum Cardiomyopathy Younger Previously healthy Few comorbidities

Bridge to Transplant

Destination Therapy REMATCH Trial 129 patients Ineligible for cardiac transplant Class IV CHF ½ received LVAD ½ received medical therapy alone Can’t get a TX – Older – Hepatitis – DM with small vessel disease Might not get a TX – Renal issues – PHTN Complex surgical

Warning Signs!!

Inability to Take CHF Therapy

Low Sodium

Cardiorenal Syndrome

Warning Signs! Recurrent Admissions Low Blood Pressure Hyponatremia Poor Renal Function Use of Continuous Inotropes Increasing diuretic dose Worsening Heart Failure Class

Bring It Home….

LANCE SULLENBERGER MD Thank You!!!